JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

33.66 -0.5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

33.37

Max

34.42

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	198
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+70.02% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.1B 2.7B
Ankstesnė atidarymo kaina	34.16
Ankstesnė uždarymo kaina	33.66

Naujienos nuotaikos

By Acuity

50%

157 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-27 23:15; UTC

Svarbiausios naujienos

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

2026-04-27 23:08; UTC

Uždarbis

Pagrindinės rinkos jėgos

LendingClub Shares Gain on 1Q Profit, Revenue Beat

2026-04-27 23:58; UTC

Uždarbis

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-27 23:58; UTC

Uždarbis

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

2026-04-27 23:56; UTC

Uždarbis

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

2026-04-27 23:56; UTC

Uždarbis

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

2026-04-27 23:48; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

2026-04-27 23:42; UTC

Rinkos pokalbiai

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

2026-04-27 23:34; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

2026-04-27 23:30; UTC

Rinkos pokalbiai

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

2026-04-27 23:08; UTC

Rinkos pokalbiai

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

2026-04-27 23:02; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-27 23:02; UTC

Rinkos pokalbiai

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

2026-04-27 22:42; UTC

Rinkos pokalbiai

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

2026-04-27 22:10; UTC

Uždarbis

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

2026-04-27 21:56; UTC

Uždarbis

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

2026-04-27 21:55; UTC

Uždarbis

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

2026-04-27 21:55; UTC

Uždarbis

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

2026-04-27 21:44; UTC

Uždarbis

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

2026-04-27 21:43; UTC

Uždarbis

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

2026-04-27 21:41; UTC

Uždarbis

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

2026-04-27 21:41; UTC

Uždarbis

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

2026-04-27 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-27 20:39; UTC

Uždarbis

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

70.02% į viršų

12 mėnesių prognozė

Vidutinis 56.6 USD 70.02%

Aukščiausias 90 USD

Žemiausias 34 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

157 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.